Telemedicine Clinical Trial
— MoVeUPOfficial title:
Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool: a Randomized, Controlled Trial
Verified date | March 2023 |
Source | IDeA States Pediatric Clinical Trials Network |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19). The hypothesis is that unvaccinated children of caregivers assigned to the Vaccine Uptake app will be more likely to achieve COVID-19 vaccine series completion than those children whose caregivers are assigned to the General Health app.
Status | Active, not recruiting |
Enrollment | 727 |
Est. completion date | December 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Parent/Caregiver Inclusion Criteria: - Age of majority, as defined by the state of residency - Access to a mobile device that can store and run the study app for 24 weeks. Devices that can run the app include mobile phones and tablets running Android or iOS operating systems - Able to speak and read in English or Spanish - Be a parent/caregiver with primary medical decision-making and legal authority to consent to vaccination decisions for at least one child who meets the child inclusion criteria Child Inclusion Criteria: - Age 6 months to less than age of majority, as defined by the child's state of residence - Has not received any doses of COVID-19 vaccine based on parent/caregiver report - Eligible to receive COVID-19 vaccine - Patient at a participating clinic Parent/Caregiver Exclusion Criteria: - Has only a child or children with known contraindication to all COVID-19 vaccines - Has only a child or children whose other parent/caregiver is already a current or past participant in the study - Has a child or children enrolled in any other COVID-19 vaccine study of any kind - Past or present participation in a COVID-19 vaccine or behavioral trial - Has a cognitive impairment that limits their ability to engage with the app content and/or make medical decisions regarding vaccination, based on the site investigator's assessment and local human subjects research policies Child Exclusion Criteria: - Not a patient of a participating clinic - Prior receipt of least one dose of COVID-19 vaccine - Receiving or scheduled to receive COVID-19 vaccination at the time of parental consent - Known medical contraindication to all COVID-19 vaccines - Ineligible to receive COVID-19 vaccine - Prior or current participation in a COVID-19 vaccine study of any kind |
Country | Name | City | State |
---|---|---|---|
United States | University of New Mexico Health Sciences Center | Albuquerque | New Mexico |
United States | Our Lady of the Lake Regional Medical Center | Baton Rouge | Louisiana |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Kapiolani Medical Center for Women and Children | Honolulu | Hawaii |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | Dartmouth Hitchcock Clinic | Lebanon | New Hampshire |
United States | Arkansas Children's Research Institute | Little Rock | Arkansas |
United States | Norton Children's Research Institute | Louisville | Kentucky |
United States | West Virginia University | Morgantown | West Virginia |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | Avera Research Institute | Sioux Falls | South Dakota |
United States | Nemours Children's Health | Wilmington | Delaware |
Lead Sponsor | Collaborator |
---|---|
IDeA States Pediatric Clinical Trials Network | National Institutes of Health (NIH), University of Montana, University of Nebraska |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of children who complete COVID-19 vaccination, as verified in state, clinic, or participant-held records | Initiation and completion of the COVID-19 vaccine series during the 24-week intervention period. Vaccine series completion will be per ACIP guidance for the vaccine product. For children who receive a product that requires more than 2 doses for the primary series, receipt of up to 3 doses will be considered complete. Vaccine doses will be valid if given within 24-week study intervention. Additional doses for primary series completion will be valid if they are in accordance with ACIP-recommended interval minus a 4-day grace period. There will be no maximum interval between valid doses. An incorrect second vaccine product (i.e., mixed series) will be invalid. The statistical team will use a mixed model with the binomial distribution and the logit link to compare the two intervention groups and the proportions of children who complete COVID-19 vaccination, using a site random effect and controlling for clustering by caregiver. | Week 24 | |
Secondary | Proportion of children who receive =1 dose of the COVID-19 vaccination series, as verified in state, clinic, or participant-held records | For each vaccine-eligible child, this secondary endpoint will be defined as whether or not the child initiates the COVID-19 vaccine series during the 16 weeks of study participation. Vaccine series initiation will be receipt of at least 1 valid dose of any COVID-19 vaccine product. Vaccine doses for series initiation will only be valid for study purposes if given within the 16 weeks of study participation. The statistical team will use a mixed model with the binomial distribution and the logit link to compare the two intervention groups with respect to the proportions of children who initiate COVID-19 vaccination, using site as a random effect and controlling for clustering by caregiver. | Week 24 | |
Secondary | Change in enrolled parent/caregiver domain scores from baseline to immediately post-intervention on the modified WHO SAGE Vaccine Hesitancy Scale adapted for the COVID-19 Vaccine | The study team will evaluate parental attitude toward pediatric COVID-19 vaccination by using the vaccine hesitancy questionnaire that includes ten statements with ordinal responses using a 5-point Likert scale. At baseline and week 16, the study statisticians will generate summary statistics for each of the 10 questions for the two intervention groups. Similarly, the change in responses from baseline to end of study will be determined for each intervention group. The study statisticians will use the general linear mixed model to evaluate the intervention effect on responses to each measure at baseline and end of study, and they will use this model to evaluate the change in each measure by using site as a random effect. Within each intervention arm and for each statement, the study statisticians will use the Wilcoxon signed rank test to determine if the change in response from baseline to end of study is significantly different from zero. | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03574480 -
Smartphone Applications to Improve Lifestyles in Olders Over 65 Years
|
N/A | |
Not yet recruiting |
NCT04070066 -
Educational Strategy IN Exchange Transfusion
|
N/A | |
Active, not recruiting |
NCT05043220 -
Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Systemic Cancer Therapy
|
N/A | |
Recruiting |
NCT04045054 -
Home-based Transitional Telecare for Older Veterans
|
N/A | |
Completed |
NCT04652674 -
Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic
|
N/A | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Recruiting |
NCT05480930 -
Improving Nighttime Access to Care and Treatment; Part 4-Haiti
|
N/A | |
Completed |
NCT03025217 -
Total Lifestyle Coaching Pilot Study (TLC)
|
N/A | |
Completed |
NCT02196428 -
Medical Telemonitoring Plus Individual Teleconsultation in Elderly
|
N/A | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Recruiting |
NCT04392518 -
Telerehabilitation in Proximal Muscle Weakness
|
N/A | |
Completed |
NCT05147038 -
The Impact of Tele-coaching on the Physical Activity Level
|
N/A | |
Not yet recruiting |
NCT05897710 -
Virtual World-Based Cardiac Rehabilitation
|
N/A | |
Not yet recruiting |
NCT04444297 -
3D Telemedicine During COVID-19: Non-clinical Validation
|
N/A | |
Not yet recruiting |
NCT04513496 -
Telemedicine in HIV Care in Buenos Aires
|
||
Completed |
NCT05895539 -
Evaluating Treatment Continuation in Telehealth Patients Receiving an Automated Patient-Reported Outcome Tool
|
N/A | |
Active, not recruiting |
NCT03474692 -
Virta Health Registry
|
||
Recruiting |
NCT05046392 -
mHealth Facilitated Intervention to Improve Medication Adherence Among Persons Living With HIV
|
N/A | |
Recruiting |
NCT05231018 -
A Study on a Digital Platform for COVID19+ Patients, Designed to Facilitate Communication and Mental-health Care During and After Hospitalization.
|
N/A | |
Recruiting |
NCT05617560 -
Hospital@Home: Telemedical Care After Inpatient Hospital Stay
|
N/A |